# CLEAR Taiwan: bempedoïnezuur verlaagt LDL met 19% in real-world Aziatische populatie

*geplaatst 2026-06-13 · Cholesterol · Journal of the American Heart Association · doi 10.1161/JAHA.126.049917 · https://hartvaat.nl/2026/05/19/clear-taiwan-bempedoinezuur-verlaagt-ldl-met-19-in-real-world-aziatische-populat/*

Pragmatische phase 4-studie bij 180 Taiwanese patiënten met onvoldoende gecontroleerde hypercholesterolemie die 12 weken bempedoïnezuur kregen toegevoegd aan hun bestaande lipidenverlagende therapie. Van de 180 patiënten voltooide 88,9% (n=160) de studie. De mediane LDL-daling vanaf baseline bedroeg -19% (IQR -36,4 tot -3,6), met een afname van 117,5 naar 92 mg/dL (p<0,01). Ook andere parameters daalden: non-HDL-cholesterol -13,3%, totaalcholesterol -10,8%, apolipoproteïne B -11,5% en hs-CRP -34,0% (alle p<0,01). Effecten op triglyceriden, HDL en Lp(a) waren minimaal. Op week 12 haalde 31,3% het LDL-doel. Het veiligheidsprofiel kwam overeen met het Taiwanese label, zonder nieuwe signalen. Bempedoïnezuur is dus een effectieve en veilige orale aanvulling voor patiënten die LDL-doelen niet halen met statines alleen.

## English: 

Pragmatic phase 4 study in 180 Taiwanese patients with inadequately controlled hypercholesterolaemia who received bempedoic acid for 12 weeks added to their existing lipid-lowering therapy. Of 180 patients, 88.9% (n=160) completed the study. Median LDL reduction from baseline was -19% (IQR -36.4 to -3.6), with a decrease from 117.5 to 92 mg/dL (p<0.01). Other parameters also fell: non-HDL cholesterol -13.3%, total cholesterol -10.8%, apolipoprotein B -11.5%, and hs-CRP -34.0% (all p<0.01). Effects on triglycerides, HDL and Lp(a) were minimal. At week 12, 31.3% met the LDL target. Safety profile matched the Taiwanese label, with no new signals. Bempedoic acid offers an effective and safe oral add-on for patients who do not reach LDL targets on statins alone.

## Abstract (original, from the publication)

BACKGROUND: Elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular disease. Despite available lipid-lowering therapies, lipid control remains suboptimal. Bempedoic acid offers a nonstatin oral treatment for hypercholesterolemia. However, real-world data in Asia are limited. The study aimed to investigate the effectiveness and safety of bempedoic acid in Taiwan. METHODS: This prospective, pragmatic phase 4 study enrolled 180 patients with inadequately controlled hypercholesterolemia to receive bempedoic acid for 12 weeks in addition to background lipid-lowering therapy. The primary end point was the percentage change in LDL-C. Secondary end points included changes in other lipid parameters, hs-CRP (high-sensitivity C-reactive protein), and safety outcomes. RESULTS: Among 180 patients, 160 (88.9%) completed the study. The median percentage change in LDL-C from baseline to week 12 was -19% (interquartile range, -36.4% to -3.6%), decreasing from 117.5 to 92 mg/dL (P<0.01). The median percentage changes from baseline to week 12 were -13.3% for non-high-density lipoprotein cholesterol, -10.8% for total cholesterol, -11.5% for apolipoprotein B, and -34.0% for hs-CRP (all P<0.01). Minimal effects were noted on triglycerides (0.2%), high-density lipoprotein cholesterol (-5.5%), and lipoprotein(a) (2.6%) (all P>0.05). At week 12, 31.3% of patients achieved LDL-C targets (<100 mg/dL for primary prevention; and <55 or <70 mg/dL for secondary prevention). The safety outcomes were consistent with the locally approved label, with no new safety signals identified. CONCLUSIONS: Bempedoic acid offers an effective and safe oral therapeutic option for Taiwanese patients whose LDL-C levels remain inadequately controlled with existing lipid-lowering therapy, including statins. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT06925100.

Auteurs: I-Chang Hsieh, Dong-Yi Chen, Chih-Sheng Chu, Yi-Yao Chang, Bing-Hsiean Tzeng, Tien-Chi Huang, Heng-Hsu Lin, Wen-Po Chuang, Chi-Cheng Huang, Jih-Kai Yeh, Chun-Yuan Chu, Ming-Yun Ho, Ching-Ya Huang, Yu-Wen Chen, Wei-Chen Yang, Tsung-Hsien Lin, Yen-Wen Wu

---
Bron: Journal of the American Heart Association, https://doi.org/10.1161/JAHA.126.049917. Bijgewerkt 2026-07-03T13:31:57Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.